STOCK TITAN

Inhibrx Biosciences (INBX) Stock Price, News & Analysis

INBX NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
60 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+36.9% close of April 22, 2026
1-year change
-1.9% closing prices, November 14, 2025 to November 16, 2026
1-month change
-13.5% closing prices, October 16, 2026 to November 16, 2026

Company Description

Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The company states that it utilizes diverse methods of protein engineering, including proprietary protein engineering platforms, to address the specific requirements of complex target and disease biology. Inhibrx Biosciences operates in the biological product manufacturing space and emphasizes therapies for oncology and, as described in several company disclosures, rare diseases.

According to multiple company press releases and SEC filings, Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX‑101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions. Inhibrx, Inc. also completed a distribution to holders of its common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following these transactions, Inhibrx Biosciences became an independent, publicly traded entity with its own clinical pipeline.

Business focus and clinical pipeline

The company describes itself as having a pipeline of novel biologic therapeutic candidates built using multivalent formats, where the precise valency can be optimized in a target-centric way to mediate what it believes to be the most appropriate agonist function. Across its public disclosures, Inhibrx Biosciences consistently identifies two core clinical programs:

  • Ozekibart (INBRX‑109) – a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit tumor‑biased cell death induced by DR5 activation. Ozekibart has been studied as a single agent and in combination regimens in several solid tumor indications, including advanced or metastatic, unresectable conventional chondrosarcoma, colorectal cancer, and Ewing sarcoma. Company communications note that ozekibart is being evaluated in a randomized, placebo‑controlled registrational trial in chondrosarcoma and in Phase 1/2 expansion cohorts in colorectal cancer and Ewing sarcoma.
  • INBRX‑106 – a precisely engineered hexavalent single-domain antibody (sdAb)–based therapeutic candidate targeting OX40, described by the company as designed to be an optimized agonist of this co‑stimulatory receptor. It is being investigated in combination with pembrolizumab (Keytruda) in patients with locally advanced or metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and non‑small cell lung cancer (NSCLC), in Phase 1/2 and Phase 2/3 clinical settings.

Inhibrx Biosciences’ public statements emphasize that both ozekibart and INBRX‑106 utilize multivalent formats intended to allow precise control over valency in a target‑centric manner. This design approach is presented by the company as central to its protein engineering strategy and as a unifying feature of its current pipeline.

Oncology and rare disease orientation

Inhibrx Biosciences repeatedly describes its focus as developing therapeutics for oncology and, in some disclosures, oncology and rare diseases. The indications highlighted in its communications include:

  • Unresectable or metastatic conventional chondrosarcoma
  • Advanced or metastatic, unresectable colorectal cancer
  • Advanced or metastatic, unresectable, relapsed, or refractory Ewing sarcoma
  • Locally advanced unresectable or metastatic head and neck squamous cell carcinoma
  • Checkpoint inhibitor refractory or relapsed non‑small cell lung cancer

The company notes that these settings often involve heavily pretreated or difficult‑to‑treat patient populations and describes unmet medical need in several of these tumor types. Inhibrx Biosciences also discloses that the U.S. Food and Drug Administration granted Fast Track designation to ozekibart for metastatic or unresectable conventional chondrosarcoma and orphan drug designation for chondrosarcoma.

Corporate history and structure

Inhibrx Biosciences’ origin is closely tied to a corporate restructuring of Inhibrx, Inc. The company reports that:

  • It was incorporated in January 2024 as a direct, wholly owned subsidiary of Inhibrx, Inc.
  • Prior to the sale of the INBRX‑101 program to Sanofi S.A., it acquired corporate infrastructure and other assets and liabilities from Inhibrx, Inc. through internal restructuring transactions.
  • Inhibrx, Inc. completed a distribution to its shareholders of 92% of the issued and outstanding shares of Inhibrx Biosciences, resulting in Inhibrx Biosciences becoming a separately traded company.

Across its press releases and SEC filings, the company refers to itself as an emerging growth company and a clinical‑stage biopharmaceutical company, with its financial reporting reflecting the spin‑off and the earlier operations of the former parent.

Regulatory and clinical development disclosures

Inhibrx Biosciences uses its SEC filings and press releases to describe the status of its clinical programs and regulatory interactions. For ozekibart, the company has publicly discussed:

  • A randomized, blinded, placebo‑controlled registrational trial in metastatic, unresectable conventional chondrosarcoma, with progression‑free survival as the primary endpoint and additional secondary endpoints such as overall survival, objective response rate, duration of response, disease control rate, quality of life, safety, pharmacokinetics, and anti‑drug antibodies.
  • Expansion cohorts in colorectal cancer in combination with FOLFIRI, and in Ewing sarcoma in combination with irinotecan and temozolomide, including interim efficacy and safety observations.
  • Plans, as described in company communications, to submit a biologics license application to the U.S. Food and Drug Administration for ozekibart following the registrational study in chondrosarcoma.

For INBRX‑106, the company has disclosed a Phase 2/3 randomized trial in combination with pembrolizumab in first‑line unresectable or metastatic HNSCC, and a Phase 1/2 trial in checkpoint inhibitor refractory or relapsed NSCLC, with endpoints such as overall response rate, disease control rate, duration of response, progression‑free survival, and safety.

Financial reporting and emerging growth status

Inhibrx Biosciences’ SEC filings and earnings press releases describe it as an emerging growth company under applicable U.S. securities regulations. The company reports research and development expenses, general and administrative expenses, other income and expense, and net income or loss, and explains that, because the spin‑off was accounted for as a reverse spin‑off, its financial statements for periods prior to the spin‑off are the historical financial statements of the former parent, Inhibrx, Inc. These disclosures provide context for how investors may interpret historical financial performance in light of the corporate restructuring and asset sale to Sanofi S.A.

Summary

Overall, Inhibrx Biosciences, Inc. presents itself, through its public disclosures, as a clinical‑stage biopharmaceutical company with a focus on oncology and rare diseases, built around proprietary protein engineering platforms and multivalent biologic formats. Its current clinical pipeline centers on ozekibart (INBRX‑109), a DR5 agonist antibody, and INBRX‑106, an OX40‑targeting sdAb‑based therapeutic candidate, both being evaluated in multiple solid tumor indications. The company’s history is closely linked to the restructuring of Inhibrx, Inc., the sale of the INBRX‑101 program to Sanofi S.A., and the distribution of Inhibrx Biosciences shares to the former parent’s shareholders.

Stock Performance

$77.66
-6.77%
-5.64
Last updated: November 16, 2026 at 16:00
-1.9%
Performance 1 year

Inhibrx Biosciences (INBX) closed at $77.66 on November 16, 2026. Over the past 12 months, the price has lost 1.9%.

See what a $1,000 investment in INBX would be worth today

Average down calculator for INBX

INBX Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Inhibrx Biosciences has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 1 article coincided with positive price movement and 8 with negative movement. Key topics include earnings, conferences, clinical trial. View all INBX news →

Insider Radar

Net Buyers
90-Day Summary
62,540
Shares Bought
2,500
Shares Sold
25
Transactions
Most Recent Transaction
Lappe Mark (Chief Executive Officer) bought 10,040 shares held indirectly at an average of $84.56 on October 14, 2026

Insider buying activity at Inhibrx Biosciences over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Inhibrx Biosciences generated $1.3M in revenue in FY2025, operating income reached -$135.0M, and net income was -$140.1M. Diluted earnings per share stood at -$9.04. The company generated -$129.8M in operating cash flow. The current ratio was 3.93, measuring current assets divided by current liabilities.

$1.3M
Revenue (FY2025)
-$140.1M
Net Income (FY2025)
-$129.8M
Operating Cash Flow

Upcoming Events

NOV
19
November 19, 2026 - November 20, 2026 Marketing

CTOS presentation

Presentation of updated ozekibart Ewing sarcoma results at CTOS conference, Nov 19–20, 2026; venue/webcast not stated.
NOV
19
November 19, 2026 Marketing

CTOS poster

CTOS in Seoul: poster on ozekibart combined with irinotecan and temozolomide in Ewing sarcoma; conference poster session.
NOV
20
November 20, 2026 Marketing

CTOS oral presentation

CTOS in Seoul: oral presentation with ChonDRAgon subgroup analysis and updated progression-free survival data for ozekibart.
Q1
2027
Q1 2027 Clinical

Phase 1 interim data

Interim data expected from newly initiated Phase 1 colorectal cancer cohorts for INBRX-109 during Q1 2027; may be webcast/disclosed.
APR
14
April 14, 2027 Regulatory

PDUFA goal date

US FDA PDUFA goal date for Ozekibart (BLA INBRX-109) decision; pivotal ChonDRAgon data supports approval consideration.
YEAR
2027
2027 Clinical

Ordastobart Phase II readout

Initial readout of ordastobart Phase 2 expansion (~50 HPV+ oropharyngeal cancer patients) expected mid-2027.
YEAR
2027
2027 Clinical

Ordastobart lung results

Initial ordastobart lung cancer results expected in mid-2027; timing approximate, no venue or webcast specified.
JUL
16
July 16, 2036 Financial

Oxford Warrants Expire

21,457 Oxford warrants exercisable immediately at $93.21 per share, expiring on 2036-07-16; ten-year term from issuance.

Inhibrx Biosciences has 8 upcoming scheduled events. The next event, "CTOS presentation", is scheduled for November 19, 2026 (in 3 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the INBX stock price.

Short Interest History

Last 12 Months

Short interest in Inhibrx Biosciences (INBX) currently stands at 3.4 million shares, down 0.8% from the previous reporting period, representing 33.8% of the float. Since November 2025, short interest has increased by 156.5%.

Days to Cover History

Last 12 Months

Days to cover for Inhibrx Biosciences (INBX) currently stands at 10.0 days, down 40.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 96.9%. Across the settlements charted above, it has ranged from 4.0 to 16.8 days.

INBX Company Profile & Sector Positioning

Inhibrx Biosciences (INBX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing INBX often look at related companies in the same sector, including Nektar Therapeutics (NKTR), Alpha Tau Medical Ltd. (DRTS), Silence Therapeutics Plc (SLN), Alto Neuroscience Inc. (ANRO), and Tyra Biosciences, Inc. (TYRA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate INBX's relative position within its industry.

Frequently Asked Questions

The current stock price of Inhibrx Biosciences (INBX) is $77.66 as of November 16, 2026.

The market cap of Inhibrx Biosciences (INBX) is approximately $1.1B. Learn more about what market capitalization means .

The FY2025 revenue of Inhibrx Biosciences (INBX) is $1.3M, from its most recent completed fiscal year.

The FY2025 net income of Inhibrx Biosciences (INBX) is -$140.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Inhibrx Biosciences (INBX) is -$9.04 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Inhibrx Biosciences (INBX) is -$129.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Inhibrx Biosciences (INBX), current assets divided by current liabilities, was 3.93 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Inhibrx Biosciences (INBX) is -$135.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

Inhibrx Biosciences, Inc. is described in its public disclosures as a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. The company states that it uses diverse methods of protein engineering, including proprietary protein engineering platforms, to address complex target and disease biology, with a focus on oncology and, in some communications, rare diseases.

Company disclosures identify two main clinical programs: ozekibart (INBRX-109), a precision-engineered tetravalent death receptor 5 (DR5) agonist antibody, and INBRX-106, a hexavalent single-domain antibody–based therapeutic candidate targeting OX40. Both use multivalent formats that the company states can be optimized in a target-centric way to mediate what it believes to be the most appropriate agonist function.

According to Inhibrx Biosciences’ press releases and SEC filings, ozekibart is being evaluated in a randomized, placebo-controlled registrational trial for advanced or metastatic, unresectable conventional chondrosarcoma. It is also being investigated in Phase 1/2 expansion cohorts in advanced or metastatic, unresectable colorectal cancer in combination with FOLFIRI and in advanced or metastatic, unresectable, relapsed, or refractory Ewing sarcoma in combination with irinotecan and temozolomide.

INBRX-106 is described by the company as a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to act as an optimized agonist of this co-stimulatory receptor. It is being studied in a Phase 2/3 randomized trial in combination with pembrolizumab (Keytruda) as first-line treatment for patients with unresectable or metastatic head and neck squamous cell carcinoma, and in a Phase 1/2 trial in checkpoint inhibitor refractory or relapsed non-small cell lung cancer, also in combination with pembrolizumab.

Inhibrx Biosciences reports that it was incorporated in January 2024 as a direct, wholly owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through internal restructuring transactions. Inhibrx, Inc. then completed a distribution of 92% of the issued and outstanding shares of Inhibrx Biosciences to its common stockholders, resulting in Inhibrx Biosciences becoming a separately traded company.

Across its press releases, Inhibrx Biosciences describes itself as focused on developing therapeutics for oncology and, in some disclosures, oncology and rare diseases. The indications highlighted include chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.

Company communications state that the U.S. Food and Drug Administration granted Fast Track designation to ozekibart for the treatment of patients with metastatic or unresectable conventional chondrosarcoma and orphan drug designation for chondrosarcoma. Inhibrx Biosciences has also discussed plans to submit a biologics license application to the FDA following its registrational chondrosarcoma trial.

Inhibrx Biosciences states that it utilizes diverse methods of protein engineering, including proprietary protein engineering platforms, to tailor biologic therapeutics to complex target and disease biology. It emphasizes multivalent formats, where precise valency can be optimized in a target-centric way, as a key feature of its current clinical candidates ozekibart and INBRX-106.

In its SEC filings, Inhibrx Biosciences indicates that it is an emerging growth company under applicable U.S. securities regulations. This status is referenced in its periodic and current reports filed with the U.S. Securities and Exchange Commission.

The company explains that the spin-off was accounted for as a reverse spin-off. As a result, for periods prior to the spin-off, Inhibrx Biosciences’ financial statements are the historical financial statements of the former parent, Inhibrx, Inc. This context is provided in its earnings press releases and SEC filings.